Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D5GVZ1
|
|||
| Drug Name |
ASP1570
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Aggressive cancer [ICD-11: 2A00-2F9Z; ICD-10: R45.6; ICD-9: 140-229] | Phase 1/2 | [1] | |
| Company |
Astelllas
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Diacylglycerol kinase zeta (DGKZ) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05083481) A Phase 1/2 Study of ASP1570 as Monotherapy and in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors. U.S.National Institutes of Health. | |||
| REF 2 | Manipulation of diacylglycerol and ERK-mediated signaling differentially controls CD8(+) T cell responses during chronic viral infection. Front Immunol. 2022 Nov 24;13:1032113. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.